JP2004231546A - Antipyretic analgesic composition - Google Patents
Antipyretic analgesic composition Download PDFInfo
- Publication number
- JP2004231546A JP2004231546A JP2003020460A JP2003020460A JP2004231546A JP 2004231546 A JP2004231546 A JP 2004231546A JP 2003020460 A JP2003020460 A JP 2003020460A JP 2003020460 A JP2003020460 A JP 2003020460A JP 2004231546 A JP2004231546 A JP 2004231546A
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- aluminum hydroxide
- antipyretic analgesic
- injury
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 239000003907 antipyretic analgesic agent Substances 0.000 title abstract description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 29
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 13
- 229940024545 aluminum hydroxide Drugs 0.000 claims abstract description 8
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000514 ethenzamide Drugs 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000004371 toothache Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 17
- 230000006378 damage Effects 0.000 abstract description 17
- 208000014674 injury Diseases 0.000 abstract description 17
- 230000002496 gastric effect Effects 0.000 abstract description 10
- 230000000202 analgesic effect Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002542 deteriorative effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229920000084 Gum arabic Polymers 0.000 description 4
- 241000978776 Senegalia senegal Species 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 3
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229960003880 bromisoval Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- -1 salicylic acid compound Chemical class 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明はイブプロフェンを配合した医薬用組成物に関する。
【０００２】
【従来の技術】
非ステロイド系抗炎症薬であるイブプロフェンは、優れた解熱鎮痛抗炎症作用を有することが知られているが、イブプロフェンを経口投与した場合、胃部での潰瘍形成などの消化管傷害を起こす可能性が指摘されている。そのため、従来、イブプロフェンによる胃傷害を軽減させることを目的としてイブプロフェンに炭酸マグネシウムおよびアルミニウムグリシネートを併用することにより胃傷害を低減させる技術（特許文献１）などが知られている。また、イブプロフェンとサリチル酸系化合物を併用することにより解熱鎮痛作用を相乗的に高める技術（特許文献２）も知られている。
【特許文献１】
特開昭６３−１９８６２０号公報
【特許文献２】
特公平４−４５４９４号公報
【０００３】
【発明が解決しようとする課題】
本発明は、イブプロフェンの優れた鎮痛効果を低下させることなく胃傷害を軽減する医薬品を提供することを目的とする。
【０００４】
【課題を解決するための手段】
本発明者らは、イブプロフェンに鎮痛効果を増強させるためのエテンザミドを組み合わせた製剤に、さらに制酸剤の配合をして胃傷害の低減を試みたところ、一般的な制酸剤を配合すると胃傷害を悪化させることがある一方、制酸剤として水酸化アルミニウムを選択した場合にのみ特異的にイブプロフェン由来の胃傷害が軽減されることを見出し本発明を完成した。
【０００５】
すなわち、本発明はイブプロフェン、エテンザミドおよび水酸化アルミニウムを配合したことを特徴とするイブプロフェン配合製剤である。
【０００６】
【発明の実施の形態】
本発明においてイブプロフェンの配合量は、通常成人に対して１日あたり１２０〜７００ｍｇになる量が好ましいが、この投与量は患者の年齢、体重、症状により適宜増減することができる。
【０００７】
本発明において水酸化アルミニウムの配合量は、イブプロフェン１質量部に対して０．１〜５質量部が好ましい。水酸化アルミニウムの配合量がこの範囲より少ないと胃傷害の改善が不十分であり、この範囲より多く配合してもそれ以上の効果は見込めないからである。
【０００８】
本発明においてエテンザミドの配合量はイブプロフェン１質量部に対して０．０５〜１０質量部が好ましい。
【０００９】
本発明の組成物は１日あたり１回ないし数回に分けて経口投与することができる。また、本発明の各成分を、複数の製剤のいずれかに配合した医薬キットとすることで、さらに効果的な医薬品とすることもできる。例えば、水酸化アルミニウムを配合した組成物とイブプロフェンおよびエテンザミドを配合した組成物とを医薬キットとすることによって、水酸化アルミニウムで胃粘膜を保護した後にイブプロフェンおよびエテンザミドを投与することにより優れた効果と胃傷害の低減を両立した製品とすることなどが考えられる。
【００１０】
本発明の医薬組成物には、必要に応じて更に鎮静催眠剤、中枢興奮剤、ビタミン剤などを適宜配合することができる。特に、カフェイン、ブロムワレリル尿素などを同時に配合すると、より良い効果の解熱鎮痛剤とすることができる。その際のイブプロフェン１質量部に対するカフェインの配合量は０．０２〜２質量部、ブロムワレリル尿素の配合量は０．１〜５質量部が好ましい。
【００１１】
本発明の医薬組成物は、一般的な賦形剤などを配合して通常の方法により錠剤、顆粒剤、細粒剤、粉剤、丸剤、カプセル剤、チュアブル剤、口腔内溶解剤、液剤などの剤形で経口製剤にすることができる。
【００１２】
【発明の効果】
本発明により、イブプロフェンの優れた鎮痛作用をそのままに、胃傷害が軽減された製剤の提供が可能になったので、頭痛、生理痛、歯痛または発熱の治療薬または予防薬として有用である。
【００１３】
【実施例】
以下、実施例および試験例により本発明をさらに詳細に説明する。
実施例１
表１に示した処方を５％アラビアゴム水溶液に懸濁して、実施例および比較例の製剤を調製した。
【００１４】
【表１】
試験例１
＜ラット胃傷害抑制効果＞
９週齢のＳＤ系雄性ラットを試験に供した。
【００１６】
ラットを１８時間絶食させた後、ステンレス製個別ケージに入れ、各被験薬を表１記載の配合量で経口投与（２ｍＬ／ｋｇ）した。また、対照群として５％アラビアゴム水溶液を投与した。この６時間後にエーテル麻酔下に胃を摘出し、１％中性緩衝ホルマリン液を約１０ｍＬ注入し、同液に浸して固定した。胃粘膜に発生した傷害の面積を実体顕微鏡にて測定し、複数の測定者の平均を傷害面積とした。
【００１７】
結果を図１に示した。
【００１８】
結果から明らかなように、イブプロフェンおよびエテンザミドを配合した製剤では、制酸剤として乾燥水酸化アルミニウムゲルを用いた処方（処方７）の場合にのみ特異的に胃傷害を低減していることが明らかになった。
【００１９】
実施例２
表２に示した処方で５％アラビアゴム水溶液に懸濁し、実施例および比較例の各被験薬を調製した。
【００２０】
【表２】
＜マウスを用いた鎮痛試験＞
１２週齢のＩＣＲ系雄性マウスを試験に供した。
【００２２】
各群１０匹とし、各被験薬および対照薬として５％アラビアゴム水溶液をそれぞれ１０ｍＬ／ｋｇ経口投与し、その３０分後に０．６％酢酸を１０ｍＬ／ｋｇ腹腔内投与した。酢酸投与１０分後から１０分間のライジング数を測定した。
【００２３】
鎮痛試験の結果を図２に示した。
【００２４】
図から明らかなように、乾燥水酸化アルミニウムゲル併用の有無に関わらず、いずれの処方も対照群に比べて有意な鎮痛作用を示し、乾燥水酸化アルミニウムゲル併用による鎮痛効果への影響は認められなかった。
【００２５】
実施例３
以下の表に示した処方で、錠剤および散剤を製造した。イブプロフェンおよびエテンザミドはそれぞれ別顆粒に造粒し、乾燥水酸化アルミニウムゲルは後末添加した。錠剤については１錠３５０ｍｇになるよう打錠して錠剤とした。散剤は１包１２００ｍｇになるように製造した。
【００２６】
なお、表において数字はｍｇを示す。
【００２７】
【表３】
【図面の簡単な説明】
【図１】各処方の胃傷害試験の結果を示した図であり、縦軸に傷害面積、横軸に各処方を示した。
【図２】各処方の鎮痛効果試験の結果を示した図であり、縦軸にライジング数、横軸に各処方を示した。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition containing ibuprofen.
[0002]
[Prior art]
Ibuprofen, a non-steroidal anti-inflammatory drug, is known to have excellent antipyretic analgesic and anti-inflammatory effects, but if ibuprofen is administered orally, it may cause gastrointestinal tract injury such as ulceration in the stomach. Has been pointed out. Therefore, conventionally, a technique for reducing gastric injury by using magnesium carbonate and aluminum glycinate in combination with ibuprofen for the purpose of reducing gastric injury due to ibuprofen is known (Patent Document 1). In addition, a technique for synergistically improving antipyretic analgesia by using ibuprofen and a salicylic acid compound in combination (Patent Document 2) is also known.
[Patent Document 1]
JP-A-63-198620 [Patent Document 2]
Japanese Patent Publication No. 4-45494
[Problems to be solved by the invention]
An object of the present invention is to provide a drug that reduces gastric injury without lowering the excellent analgesic effect of ibuprofen.
[0004]
[Means for Solving the Problems]
The present inventors have attempted to reduce gastric injury by further adding an antacid to a formulation in which ibuprofen is combined with etenzamide to enhance the analgesic effect. The present inventors have found that while injuries may be worsened, gastric injury derived from ibuprofen is specifically reduced only when aluminum hydroxide is selected as an antacid.
[0005]
That is, the present invention is an ibuprofen-containing preparation, comprising ibuprofen, etensamide and aluminum hydroxide.
[0006]
BEST MODE FOR CARRYING OUT THE INVENTION
In the present invention, the amount of ibuprofen to be blended is preferably 120 to 700 mg per day for an adult, but the dose can be appropriately adjusted according to the age, weight, and symptoms of the patient.
[0007]
In the present invention, the compounding amount of aluminum hydroxide is preferably 0.1 to 5 parts by mass with respect to 1 part by mass of ibuprofen. If the amount of aluminum hydroxide is less than this range, improvement of gastric injury is insufficient, and if it is more than this range, no further effect can be expected.
[0008]
In the present invention, the blending amount of ethenzamide is preferably 0.05 to 10 parts by mass with respect to 1 part by mass of ibuprofen.
[0009]
The composition of the present invention can be orally administered once or several times a day. In addition, a more effective pharmaceutical product can be obtained by preparing a pharmaceutical kit in which each component of the present invention is mixed with any of a plurality of preparations. For example, by making a composition containing aluminum hydroxide and a composition containing ibuprofen and etenzamide into a pharmaceutical kit, by administering ibuprofen and etenzamide after protecting the gastric mucosa with aluminum hydroxide, excellent effects and It is conceivable to make the product compatible with reducing stomach injury.
[0010]
The pharmaceutical composition of the present invention may optionally further contain a sedative-hypnotic, a central stimulant, a vitamin, and the like, if necessary. In particular, when caffeine, bromvalerylurea and the like are simultaneously added, a more effective antipyretic analgesic can be obtained. In this case, the compounding amount of caffeine is preferably 0.02 to 2 parts by mass, and the compounding amount of bromovaleryl urea is preferably 0.1 to 5 parts by mass with respect to 1 part by mass of ibuprofen.
[0011]
The pharmaceutical composition of the present invention is prepared by mixing ordinary excipients and the like, and by ordinary methods, tablets, granules, fine granules, powders, pills, capsules, chewables, oral dissolving agents, liquids, etc. Oral formulation in the form of
[0012]
【The invention's effect】
INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide a preparation with reduced gastric injury while retaining the excellent analgesic action of ibuprofen, and thus it is useful as a therapeutic or preventive agent for headache, menstrual pain, toothache or fever.
[0013]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples.
Example 1
The formulations shown in Table 1 were suspended in a 5% aqueous solution of gum arabic to prepare formulations of Examples and Comparative Examples.
[0014]
[Table 1]
Test example 1
<Effect of suppressing rat stomach injury>
Nine-week-old male SD rats were subjected to the test.
[0016]
After the rats were fasted for 18 hours, they were placed in individual stainless steel cages, and each test drug was orally administered (2 mL / kg) at the compounding amount shown in Table 1. As a control group, a 5% gum arabic aqueous solution was administered. Six hours later, the stomach was removed under ether anesthesia, and about 10 mL of a 1% neutral buffered formalin solution was injected, and immersed and fixed in the same solution. The area of the injury generated in the gastric mucosa was measured with a stereoscopic microscope, and the average of a plurality of measurers was defined as the injury area.
[0017]
The results are shown in FIG.
[0018]
As is clear from the results, it is clear that the preparation containing ibuprofen and etensamide specifically reduces gastric injury only in the case of a preparation using dry aluminum hydroxide gel as an antacid (formulation 7). Became.
[0019]
Example 2
Each of the test drugs of Examples and Comparative Examples was suspended in a 5% aqueous solution of gum arabic according to the formulation shown in Table 2.
[0020]
[Table 2]
<Analgesia test using mice>
12-week-old ICR male mice were subjected to the test.
[0022]
Each group consisted of 10 animals, and each test or control drug was orally administered with a 5% aqueous solution of gum arabic at 10 mL / kg, and 30 minutes later, 0.6% acetic acid was intraperitoneally administered at 10 mL / kg. From 10 minutes after the administration of acetic acid, the number of risings for 10 minutes was measured.
[0023]
The results of the analgesic test are shown in FIG.
[0024]
As is evident from the figure, regardless of the presence or absence of the dry aluminum hydroxide gel combination, all the formulations showed a significant analgesic effect compared to the control group, and the effect of the dry aluminum hydroxide gel combination on the analgesic effect was observed. Did not.
[0025]
Example 3
Tablets and powders were prepared with the formulation shown in the table below. Ibuprofen and etensamide were each granulated separately, and dried aluminum hydroxide gel was added at the end. The tablets were tableted to give a tablet weight of 350 mg. The powder was prepared so as to be 1200 mg per packet.
[0026]
The numbers in the table indicate mg.
[0027]
[Table 3]
[Brief description of the drawings]
FIG. 1 is a diagram showing the results of a gastric injury test of each formulation, in which the vertical axis shows the injury area and the horizontal axis shows each formulation.
FIG. 2 is a diagram showing the results of an analgesic effect test of each formulation, in which the vertical axis represents the number of writhings and the horizontal axis represents each formulation.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003020460A JP4947609B2 (en) | 2003-01-29 | 2003-01-29 | Antipyretic analgesic composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003020460A JP4947609B2 (en) | 2003-01-29 | 2003-01-29 | Antipyretic analgesic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004231546A true JP2004231546A (en) | 2004-08-19 |
| JP4947609B2 JP4947609B2 (en) | 2012-06-06 |
Family
ID=32950088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003020460A Expired - Lifetime JP4947609B2 (en) | 2003-01-29 | 2003-01-29 | Antipyretic analgesic composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4947609B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009242365A (en) * | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | Oral pharmaceutical composition |
| JP2009242360A (en) * | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | Orally administrable chronic pain preventing or treating agent |
| WO2014017507A1 (en) * | 2012-07-27 | 2014-01-30 | 大正製薬株式会社 | Solid pharmaceutical preparation |
| JP2014141469A (en) * | 2012-12-27 | 2014-08-07 | Taisho Pharmaceutical Co Ltd | Layering particle |
| EP2881111A4 (en) * | 2012-08-03 | 2015-12-16 | Univ Ehime | Immune cell activation inhibitor and use thereof |
-
2003
- 2003-01-29 JP JP2003020460A patent/JP4947609B2/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009242365A (en) * | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | Oral pharmaceutical composition |
| JP2009242360A (en) * | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | Orally administrable chronic pain preventing or treating agent |
| WO2014017507A1 (en) * | 2012-07-27 | 2014-01-30 | 大正製薬株式会社 | Solid pharmaceutical preparation |
| JPWO2014017507A1 (en) * | 2012-07-27 | 2016-07-11 | 大正製薬株式会社 | Solid preparation |
| EP2881111A4 (en) * | 2012-08-03 | 2015-12-16 | Univ Ehime | Immune cell activation inhibitor and use thereof |
| US9517217B2 (en) | 2012-08-03 | 2016-12-13 | Ehime University | Immune cell activation inhibitor and use thereof |
| JP2014141469A (en) * | 2012-12-27 | 2014-08-07 | Taisho Pharmaceutical Co Ltd | Layering particle |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4947609B2 (en) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4445590B2 (en) | Oral liquid composition containing paroxetine-resin | |
| JP6139743B2 (en) | Loxoprofen-containing pharmaceutical composition | |
| JPS60208913A (en) | Pharmaceutical product rendering improved analgesia | |
| JP5465824B2 (en) | Pharmaceutical preparation and method for producing the same | |
| AU2018420535B2 (en) | Edaravone pharmaceutical composition | |
| JP2010168373A (en) | Loxoprofen-containing pharmaceutical composition | |
| JP3122748B2 (en) | Antipyretic analgesic containing ibuprofen | |
| JP2008247822A (en) | Analgesic composition | |
| JP2004231546A (en) | Antipyretic analgesic composition | |
| KR20130141622A (en) | Antipyretic/analgesic composition | |
| JP3982889B2 (en) | Pharmaceutical preparations containing ibuprofen | |
| JP2000159674A (en) | Antipyretic analgesic antiphlogistic | |
| TW201416072A (en) | Stabilized solid preparation for internal use | |
| CZ79593A3 (en) | Antitussive preparation | |
| RU2009121838A (en) | ORAL DOSAGE FORM CONTAINING COMPOUNDS OF TRIZOMISED GLYCERINE | |
| JPH0834728A (en) | Ibuprofen preparation | |
| JP2007137896A (en) | Ibuprofen-containing pharmaceutical preparation | |
| JP6197515B2 (en) | Pharmaceutical composition | |
| KR100379155B1 (en) | New analgesic composition | |
| RU2751351C2 (en) | Oral ibuprofen medication | |
| JP2014070024A (en) | Pharmaceutical composition containing phenylpropionic acid-based anti-inflammatory analgesic agent | |
| JP4993998B2 (en) | Pharmaceutical composition containing ibuprofen | |
| TW200826923A (en) | A composition for the treatment and prevention of peptic ulcer | |
| JPS61134315A (en) | Antipyretic and analgesic agent | |
| JP2004331660A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051227 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090623 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090812 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090902 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20091026 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091026 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120301 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4947609 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |